SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical’s Q3 consolidated net profit rises by 32%

08 Feb 2013 Evaluate

Healthcare firm Sun Pharmaceutical has reported result for third quarter ended December 31, 2012.

The company’s net profit for the quarter declined by 79.67% at Rs 74.22 crore as compared to Rs 365.23 crore for the same quarter in the previous financial year. Total income of the company declined by 6.80% at Rs 910.36 crore for quarter under review as compared to Rs 976.78 crore for the quarter ended December 31, 2011.

On consolidated basis, the group’s net profit after taxes and minority interest for the quarter jumped by 31.87% at Rs 881.30 crore for the quarter as compared to Rs 668.30 crore for the same quarter in the previous year. Total income of the company has increased by 38.64% at Rs 2933.33 crore for quarter as compared to Rs 2115.70 crore for the quarter ended December 31, 2011.

Dusa Pharmaceuticals, Inc (Dusa), a pharmaceutical company, incorporated in United States (US) became a subsidiary of the Company on December 20, 2012. Accordingly, the results for the current periods include the relevant results of Dusa (which includes Rs 2,830 lakhs on account of onetime employees severance cost) from the date Dusa became subsidiary of the Company and therefore the corresponding figures for the previous periods are not comparable.

Sun Pharma Inds. Share Price

1654.70 -62.65 (-3.65%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×